Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CKDB-501A (serotype A botulinum toxin) is a novel BoNT/A neuromodulator protein. It is being evaluated for the treatment of moderate-to-severe glabellar lines.
Lead Product(s): Serotype A Botulinum Toxin
Therapeutic Area: Dermatology Product Name: CKDB-501A
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Healis Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
Under the agreement, Healis intends to develop CKDB-501, a neuromodulator Serotype A botulinum toxin (BoNT/A) protein, for Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD).
Lead Product(s): CKDB-501
Therapeutic Area: Psychiatry/Psychology Product Name: CKDB-501
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Healis Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 02, 2024